Mendus Ab Stock Net Income
| IMMU Stock | SEK 4.85 0.05 1.02% |
As of the 18th of February 2026, Mendus AB secures the Standard Deviation of 3.9, risk adjusted performance of (0.04), and Mean Deviation of 2.87. Mendus AB technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices.
Analyzing historical trends in various income statement and balance sheet accounts from Mendus AB's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Mendus AB's valuation are summarized below:Mendus AB does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Mendus |
Mendus AB 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Mendus AB's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Mendus AB.
| 11/20/2025 |
| 02/18/2026 |
If you would invest 0.00 in Mendus AB on November 20, 2025 and sell it all today you would earn a total of 0.00 from holding Mendus AB or generate 0.0% return on investment in Mendus AB over 90 days. Mendus AB is related to or competes with Ascelia Pharma, Intervacc, Magle Chemoswed, Xintela AB, Moberg Pharma, Elicera Therapeutics, and Karolinska Development. Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer and Phase IbII c... More
Mendus AB Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Mendus AB's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Mendus AB upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 21.62 | |||
| Value At Risk | (6.02) | |||
| Potential Upside | 6.32 |
Mendus AB Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mendus AB's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Mendus AB's standard deviation. In reality, there are many statistical measures that can use Mendus AB historical prices to predict the future Mendus AB's volatility.| Risk Adjusted Performance | (0.04) | |||
| Jensen Alpha | (0.24) | |||
| Total Risk Alpha | (0.46) | |||
| Treynor Ratio | 0.7056 |
Mendus AB February 18, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | 0.7156 | |||
| Mean Deviation | 2.87 | |||
| Coefficient Of Variation | (1,610) | |||
| Standard Deviation | 3.9 | |||
| Variance | 15.24 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.24) | |||
| Total Risk Alpha | (0.46) | |||
| Treynor Ratio | 0.7056 | |||
| Maximum Drawdown | 21.62 | |||
| Value At Risk | (6.02) | |||
| Potential Upside | 6.32 | |||
| Skewness | 0.557 | |||
| Kurtosis | 1.39 |
Mendus AB Backtested Returns
Mendus AB has Sharpe Ratio of -0.0464, which conveys that the firm had a -0.0464 % return per unit of risk over the last 3 months. Mendus AB exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Mendus AB's Mean Deviation of 2.87, risk adjusted performance of (0.04), and Standard Deviation of 3.9 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of -0.36, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Mendus AB are expected to decrease at a much lower rate. During the bear market, Mendus AB is likely to outperform the market. At this point, Mendus AB has a negative expected return of -0.18%. Please make sure to verify Mendus AB's treynor ratio, potential upside, and the relationship between the total risk alpha and maximum drawdown , to decide if Mendus AB performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.58 |
Good reverse predictability
Mendus AB has good reverse predictability. Overlapping area represents the amount of predictability between Mendus AB time series from 20th of November 2025 to 4th of January 2026 and 4th of January 2026 to 18th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Mendus AB price movement. The serial correlation of -0.58 indicates that roughly 58.0% of current Mendus AB price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.58 | |
| Spearman Rank Test | -0.24 | |
| Residual Average | 0.0 | |
| Price Variance | 0.17 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Mendus AB reported net income of (130.1 Million). This is 138.12% lower than that of the Healthcare sector and 285.74% lower than that of the Biotechnology industry. The net income for all Sweden stocks is 122.79% higher than that of the company.
Mendus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mendus AB's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mendus AB could also be used in its relative valuation, which is a method of valuing Mendus AB by comparing valuation metrics of similar companies.Mendus AB is currently under evaluation in net income category among its peers.
Mendus Fundamentals
| Return On Equity | -0.21 | |||
| Return On Asset | -0.11 | |||
| Operating Margin | (69.15) % | |||
| Current Valuation | 607.17 M | |||
| Shares Outstanding | 199.4 M | |||
| Shares Owned By Insiders | 57.54 % | |||
| Shares Owned By Institutions | 11.78 % | |||
| Price To Earning | (4.53) X | |||
| Price To Book | 1.13 X | |||
| Price To Sales | 354.29 X | |||
| Gross Profit | 6 K | |||
| EBITDA | (128.28 M) | |||
| Net Income | (130.1 M) | |||
| Cash And Equivalents | 155.31 M | |||
| Cash Per Share | 3.94 X | |||
| Debt To Equity | 0.20 % | |||
| Current Ratio | 14.67 X | |||
| Book Value Per Share | 2.81 X | |||
| Cash Flow From Operations | (138.03 M) | |||
| Earnings Per Share | (0.63) X | |||
| Target Price | 6.75 | |||
| Number Of Employees | 31 | |||
| Beta | 1.04 | |||
| Market Capitalization | 427.98 M | |||
| Total Asset | 720.98 M | |||
| Retained Earnings | (100 M) | |||
| Working Capital | 36 M | |||
| Current Asset | 45 M | |||
| Current Liabilities | 9 M | |||
| Net Asset | 720.98 M |
About Mendus AB Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mendus AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mendus AB using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mendus AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mendus Stock Analysis
When running Mendus AB's price analysis, check to measure Mendus AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mendus AB is operating at the current time. Most of Mendus AB's value examination focuses on studying past and present price action to predict the probability of Mendus AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mendus AB's price. Additionally, you may evaluate how the addition of Mendus AB to your portfolios can decrease your overall portfolio volatility.